Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

36.73 USD +0.03 (+0.08%)
Official Closing Price Updated: 7:59 PM EST, Jan 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Pfizer

< Previous 1 2
...
93 94 95 96 97 98 99 100 Next >
Pfizer to Present Data from Its Hematology Portfolio at the 52nd Annual Meeting of the American Society of Hematology
Company to Present Phase 3 Data Studying Bosutinib in Chronic Myeloid Leukemia 
From PR Newswire
Pfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease
From PR Newswire
Pfizer Extends Tender Offer to Acquire King Pharmaceuticals, Inc.
From PR Newswire
The NASDAQ OMX CRD Global Sustainability 50 Index Expands to 100 Companies and Releases Semi-Annual Evaluation Results
From GlobeNewswire News Releases
Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
Detailed Study Results Expected to be Presented at an Upcoming Medical Meeting 
From PR Newswire
APPRAISE-2 Study with Investigational Compound Apixaban in Acute Coronary Syndrome Discontinued
From Business Wire News Releases
Pfizer Launches New Advil® Congestion Relief and Offers 100 Holiday Shoppers Literal Decongestion From Black Friday Crowds
Survey Reports Nearly 70 Percent of People Avoid Crowded Areas During the Holidays(1) 
From PR Newswire
Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
Anthony J. Coyle, Ph.D. Will Head the Network that Aims to Accelerate and Transform Drug Discovery and Development 
From PR Newswire
Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
Rates of Heart Failure Hospitalization, All-Cause Hospitalization, and All-Cause Mortality also Significantly Reduced 
From PR Newswire
Lower Protein in Infant Formula Supports Growth Rate Similar to Breast Milk, New Study Shows
From PR Newswire
Biovista Announces a Drug Repositioning Collaboration With Pfizer
From PR Newswire
Alpine Mountaineer and Alzheimer's Advocate to Climb Highest Peak on Each Continent to Raise Awareness of Growing Prevalence and Burden of Alzheimer's Disease
- Alan Arnette, Caregiver to His Mother, Now Dedicates Challenging Climbs to Her Memory and Others Caring for Alzheimer's Patients - 
From PR Newswire
S&P Equity Research Services Publishes Quality Trends, an In-Depth Analysis of 'Quality' in the Equity Markets
S&P Recommends Investors Begin Rotating Into High Quality Ranking Issues Now 
From PR Newswire
Progenics Pharmaceuticals Announces Third Quarter 2010 Financial Results
From Business Wire News Releases
In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function
Tasocitinib Demonstrates Sustained Efficacy at 24 Months in Phase 2/3 Open Label Extension Study 
From PR Newswire
Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
Collaboration Aims to Empower Patients with Psoriatic Arthritis and Rheumatoid Arthritis to Seek Care 
From PR Newswire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
From PR Newswire
Pfizer Reports Third-Quarter 2010 Results
From PR Newswire
Pfizer's Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan
First Treatment Approved for Common Pain Conditions Filling Important Unmet Need for Patients in Japan 
From PR Newswire
Pfizer Declares an 18-Cent Fourth-Quarter 2010 Dividend
From PR Newswire
Critical Alerts for Amazon.com, Pfizer, Motorola, Pioneer Natural Resources, and CB Richard Ellis Released by Seven Summits Research
From PR Newswire
Pain Therapeutics Reports Third Quarter 2010 Financial Results
From GlobeNewswire News Releases
Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Cri
First-in-Class ALK Inhibitor Rapidly Advanced to Phase 3 Development 
From PR Newswire
Pain Therapeutics Declares Special One-Time Cash Distribution to Shareholders
From GlobeNewswire News Releases
Wall Street News Alert: Hot Stock to Watch: Unity Management Group -- October 27, 2010
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding. 
From Marketwired News Releases
Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
From PR Newswire
New Phase 4 Study Shows Higher Rates of Clinical and Microbiological Success for Zyvox Versus Vancomycin in MRSA Nosocomial Pneumonia
Findings From Largest MRSA Nosocomial Pneumonia Study Conducted to Date Were Presented During IDSA Annual Meeting 
From PR Newswire
Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
Phase III Treatment-naive and Treatment-experienced Trials Underway for S/GSK1349572 ('572) 
From PR Newswire
Centrum® Encourages Women to Pledge to Take Time for Life's Greatest Pleasures
Survey Finds That Lack of Energy is Taking its Toll on Lifestyles of Nearly Three-Quarters of Women(1) 
From PR Newswire
Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
Transaction will expand portfolio of generic medicines in Brazil 
From PR Newswire
< Previous 1 2
...
93 94 95 96 97 98 99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.